OTGR gets tough on GM field trials
05 June, 2002 by Melissa TrudingerThe Office of the Gene Technology Regulator (OGTR) has moved to tighten procedures for post-harvest monitoring and strengthen the management of GM field trials performed under the new regulatory system.
EvoGenix partners with BresaGen
04 June, 2002 by Iain ScottBiotech start-up EvoGenix has teamed with Adelaide-based company BresaGen to work on a protein biopharmaceutical project.
New procedure for those that kneed it
04 June, 2002 by Claire DobleA new procedure for knee replacement, in which cultured cartilage cells grow themselves into place, is available now for Australian patients.
Antisense offers key to new MS treatment
04 June, 2002 by Melissa TrudingerA new way to treat multiple sclerosis (MS) with antisense drugs is being developed by Melbourne company Antisense Therapeutics with the assistance of its US partner Isis Pharmaceuticals.
Eye researcher wins award
04 June, 2002 by Tanya HollisDedication to warding off a common form of blindness has earned a Melbourne ophthalmologist the 2002 Amgen Medical Researcher Award.
GroPep restructures, outlines new directions
04 June, 2002 by Tanya HollisAdelaide growth factor biobusiness GroPep has laid out its path to profits by announcing plans to concentrate on growing its pharmaceutical cell culture division.
Greenpeace launches GE shopping guide
03 June, 2002 by Claire DobleAustralian cookbook icon Margaret Fulton joined Greenpeace at Sydney's Fox Studios on Friday last week to launch the environmental campaigner's True Food Guide book.
Trans-Tasman biotech collaborations sought
03 June, 2002 by Pete YoungNew Zealand's political leadership is declaring the Land of the Long White Cloud open for collaborative ventures with Australia's biotech sector.
Peptech upbeat despite half year loss
31 May, 2002 by David BinningAustralian biotechnology company Peptech posted a net loss of $4.6 million on Wednesday for the half-year ended March 31, 2002, but said that the progress of key patents in the US would guarantee meaningful new revenue streams going forward.
Biotechs need to focus on early-stage R&D: experts
31 May, 2002 by Tanya HollisAustralia's biotech sector needed to focus on improving early stage compound validation to reduce the exorbitant costs of project attrition, experts said yesterday.
No plans to slow down for Austin's retiring director
30 May, 2002 by Tanya HollisWhen Nobel medicine laureate Dr George Snell accepted his 1980 award for identifying genetically determined cell surface immune response regulators, six peers received his thanks. One was an Australian - Prof Ian McKenzie.
Meditech snares Moses for board
30 May, 2002 by Tanya HollisDrug delivery company Meditech Research has named sought-after business analyst Bob Moses as chairman of its board.
New study of testosterone deficiency
29 May, 2002 by Tanya HollisA collaboration between men's health specialists and pathologists aims to create a precision reference kit to diagnose testosterone deficiency in men.
Monsanto, Aventis to bid for GM canola production
29 May, 2002 by Melissa TrudingerMonsanto has confirmed that it is getting ready to file its submission for commercial production of its GM Roundup Ready canola variety to the Office of the Gene Technology Regulator (OGTR).
States flex their muscles over GM-free zones
29 May, 2002 by Pete YoungThe rights of the states to designate agricultural zones in which genetically modified crops can be either banned or permitted has been reinforced by the body overseeing the national regulatory framework for gene technology.
